Freeman · Addiction (Abingdon, England) 2014 · Cross-sectional naturalistic observational study · n=247

Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?

Cited 140 times in the scientific literature.

Level 4 - case-series / case-control

Cross-sectional observational study

PubMed 24894801 · doi:10.1111/add.12634 · record verified 2026-08-26

What was done

A cross-sectional, naturalistic study evaluated 247 cannabis users in the United Kingdom (152 recreational users [1–24 days/month] and 95 daily users [≥25 days/month]) in their homes. Participants rated their own cannabis for potency on a 1–10 scale and classified its type (resin, herbal, or skunk) before rolling a joint in front of the researcher. The amount of cannabis used per joint (in grams) was weighed, and an additional sample was analyzed in a laboratory to measure delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations (%).

What was found

Higher THC concentration was negatively associated with the amount of cannabis rolled into joints (unstandardized regression coefficient b = -0.009, 95% CI: -0.017 to -0.002). Subjective potency ratings were predicted by increasing THC (b = 0.055, 95% CI: 0.020 to 0.090) and decreasing CBD (b = -0.160, 95% CI: -0.284 to -0.062), with both associations mediated by cannabis type (THC mediation: b = 0.018, 95% CI: 0.006 to 0.037; CBD mediation: b = -0.105, 95% CI: -0.198 to -0.028). Potency estimates reflected measured THC more strongly as frequency of use increased (b = 0.004, 95% CI: 0.001 to 0.007), showing a 7.3-fold stronger correlation in daily users (partial r = 0.381) than in recreational users (r = 0.052).

Why it matters

This study shows that cannabis users naturally titrate joint weight according to THC content rather than CBD. However, recreational users show poor awareness of actual potency, highlighting potential risks of misjudging dose in non-daily consumers.

Limits

The study relied on a cross-sectional design in a single country (UK). It evaluated only joint-rolling behavior and did not measure other consumption methods (such as vaporizers or edibles) or actual blood cannabinoid levels and inhaled doses.

Cited by